About

Company description

Protect and grow your ingredient portfolio
Siftlink helps business and product development teams of ingredient suppliers and consumer health, food and beverage brands decide in which ingredient to invest next. We bring science, clinical evidence, patents, regulation and market data together in one AI model, so you see risks and opportunities on your ingredients earlier and back the products most likely to succeed. At Fi Europe we offer the Precision Innovation sprint that help design a differentiated product or portfolio in six weeks, with clinical, patent and commercial strategy aligned from day one.
Why it matters
Claims are moving faster than evidence, and demand is not where the research is. In our analysis of 216,350 consumer comments, sleep made up 39% of the discussion but only 3% of clinical trials. Suppliers of botanical ingredients find it hard to differentiate when the clinical evidence is shared by everyone selling the same species, while brands need actives and compositions their competitors cannot copy. And the data needed to decide sits in separate systems and teams. Siftlink connects it.

Precision Innovation sprint
Our method rests on one principle: right composition x right application x right people = efficacy. The ingredient molecule is fixed, but the combination, ratios, delivery system, benefit and target consumer are open, and that design space is built from ingredients already safe and permitted for sale. Over six weeks, our team and AI platform work with yours on four questions:

• What to develop: ingredients and compositions ranked against your target benefit, including ingredients with no clinical history.
• Which claims will hold: endpoints and biomarkers prioritized, with a predicted probability that a study meets its primary endpoint before you fund it.
• Whether you can own it: novelty, whitespace and freedom to operate assessed while the formulation can still change.
• Who it is for and what it is worth: target consumer and business forecast, each with a confidence range.

Proof, not promises

• Clinical trial prediction: shown one trial that met its primary endpoint and one that did not, our model picks the successful one 89 times in 100 (chance is 50), tested on trials that read out after its training data (ROC-AUC 0.893).
• Consumer insight with clinical signal: in our medRxiv preprint (June 2026), benefits reported by 100 or more consumers had a 38% chance of randomised trial support, against 9% overall.
• Track record: 19 programs delivered for multinationals and SMEs, 3 patents filed, Innosuisse Innovation Booster 2023.
• Team: decades of R&D, patent and AI experience across multinational food, nutrition and biotech companies.

Meet us at stand 41S11

Quick facts

Primary business activity	Consulting

Upcoming events

Recently at